

**DETECTION OF RECEPTOR FOR ALFA FETO-
PROTEIN (RECAF) IN B- NON-HODGKIN'S
LYMPHOMA BY IMMUNOHISTOCHEMICAL
TECHNIQUES; ITS CORRELATION TO
INFILTRATION BY HISTOPATHOLOGY**

Thesis

**Submitted for Partial Fulfillment of the Master
Degree in Clinical Pathology**

By

Heba Fawzy Houssein Ibrahim

M.B., B.Ch.

Supervisors

Professor/ Hebatallah Adel Sedky

**Prof. of Clinical Pathology,
Faculty of Medicine, Ain Shams University**

Professor/ Soha Raouf Youssef

**Prof. of Clinical Pathology,
Faculty of Medicine, Ain Shams University**

Doctor/ Doaa Ahmed Gamal Eissa

**Lecturer of Clinical Pathology,
Faculty of Medicine, Ain Shams University**

**Faculty of Medicine,
Ain Shams University
2011**

اكتشاف مستقبلات الألفا فيتوبروتين (ريكاف) في
نخاع العظام في حالات أورام الغدد الليمفاوية
الغير هودجكيني النوع (ب) باستخدام التحليل
المناعي الكيميائي وعلاقته بالطرق التقليدية في
اكتشاف الخلايا السرطانية

رسالة

توطئة للحصول على درجة الماجستير في
الباثولوجيا الاكلينيكية

مقدمة من

الطبيبة/ هبة فوزي حسين ابراهيم

تحت إشراف:

الأستاذ الدكتور/ هبة الله عادل صدقي

أستاذ الباثولوجيا الاكلينيكية
كلية الطب- جامعة عين شمس

الاستاذ الدكتور/سها رؤوف يوسف

أستاذ الباثولوجيا الاكلينيكية
كلية الطب-جامعة عين شمس

الدكتور/دعاء أحمد جمال عيسى

مدرس الباثولوجيا الاكلينيكية
كلية الطب-جامعة عين شمس

كلية الطب

جامعة عين شمس

2011

SUMMARY

Lymphomas constitute a broad group of tumors of the immune system that continue to challenge oncologists. The dynamics of lymphoma entails that it must be handled through a multi-disciplinary approach. The last decade has witnessed marked change in the profile of malignant lymphoma (*Holte et al., 2009*).

Lymphomas are divided into Non-Hodgkin's Lymphoma (NHL) and Hodgkin's disease (HD). Non-Hodgkin's Lymphoma occurs roughly three times as frequent as Hodgkin's disease (HD) (*Friedberg et al., 2008*).

In Egypt, malignant lymphomas are relatively common. The exact national incidence is not precisely known due to absence of a National Cancer Registry and the only data available are from hospital registries. At Ain Shams Radiation Oncology and Nuclear Medicine Department (RONMD), the total number of cancer cases from 2004 to 2006) was 4046 cases, with 413 lymphoma cases constituting 10.2% of cases. Relative predominance of NHL over HD was at a rate of 2: 1 (*Ibrahim et al., 2008*).

ACKNOWLEDGMENT

First of all, thanks to GOD for helping me to complete this work.

*I would like to express my deep gratitude and appreciation to **Professor Hebatallah Adel Sedky**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her valuable knowledge, meticulous supervision and faithful assistance during this work. Words of thanks are little to express my gratefulness for her.*

*I am also deeply grateful to **Professor. Soha Raouf Youssef**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her sincere guidance and continuous encouragement during this work.*

*I am also grateful to **Dr. Doaa Ahmed Gamal Eissa**, Lecturer of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her sincere guidance and continuous encouragement during this work.*

Heba fawzy Houssein Ibrahim

LIST OF CONTENTS

Subjects	Page
* Introduction & Aim of the Work	1
* B-Non-Hodgkin's Lymphoma	5
* Diagnosis of B-Non-Hodgkin's Lymphoma	29
* Alpha Fetoprotein	70
* RECAF	76
* Subjects and Methods	88
* Results	100
* Discussion	142
* Summary	152
* References	158
* Arabic Summary.	

LIST OF TABLES

Table No.	Title	Page
1	Known Risk Factors of NHL.....	16
2	WHO Classification of mature B-Cell Lymphoid Neoplasms, 2008.....	18
3	WHO Classification of mature T-and NK-Cell Lymphoid Neoplasms, 2008	19
4	Cotswolds modification of Ann Arbor Staging System	26
5	Revised Response Criteria for Lymphoma	28
6	Types of Tissue Fixatives	49
7	Differential Diagnosis of B-NHL by IHC	57
8	Descriptive Data of Normal Control group included in the study	112
9	Descriptive Data of Pathological Control group included in the study	112
10	Descriptive Data of Cases group included in the study (total).	113
11	Descriptive Data of Cases subgroups included in the study	114
12	comparative Data of Main groups included in the study	115

LIST OF TABLES (CONT.)

Table No.	Title	Page
13	Comparison between DLBCL, FL and MCL Subgroups.	115
14	Comparison between CLL Subgroup and each of DLBCL, FL and MCL.	116
15	Comparison between HCL Subgroup and the Main subgroups (DLBCL, FL and MCL Subgroups).	116
16	Comparison between CLL and HCL Subgroups	117
17	Comparison between Non-Quantitative Data in Subgroups of Cases Group.	117
18	Comparison between Quantitative Data in Subgroups of Cases Group	118
19	Comparison between different subgroups included in the study as regards ROC curve	119
20	comparison between NC, PC and cases as regards percent of RECAF positive cases	119
21	comparison between B-NHL subgroups as regards percent of RECAF positive cases	120
22	Comparison between RECAF negative and RECAF positive in the cases involved in the study as regards clinical findings:	120
23	Comparison between RECAF negative and RECAF positive in the cases involved in the study as regards laboratory findings:	121
24	Comparison between routine histopathology and RECAF as regards BM infiltration	121

LIST OF FIGURES

Figure No.	Title	Page
1	The Anatomy of a Lymph Node	6
2	The Anatomy of Spleen	7
3	Hypothetical scheme of lymphocyte differentiation.....	9
4	Differentiation scheme, showing nomenclature for various types of T cells (top) and B cells (bottom)	11
5	Differentiation scheme, showing postulated normal counterpart of many of the T- and B-cell neoplasms	14
6	B-Lymphoblastic lymphoma	33
7	Small lymphocytic lymphoma in Lymph Node by Low Power showing diffuse effacement of Nodal Architecture	33
8	Small lymphocytic lymphoma by High power.....	34
9	Lymphoplasmacytic lymphoma in Bone Marrow Biopsy....	35
10	Hairy Cell Leukemia.	35
11	Hairy Cell Leukemia in stained smear	36
12	Spleen; marginal zone lymphoma	37
13	Follicular lymphoma with aggregates of lymphoma cells throughout the lymph node	39

LIST OF FIGURES (CONT.)

Figure No.	Title	Page
14	Follicular lymphoma at high magnification showing small lymphoid cells with condensed chromatin and irregular or cleaved nuclear outlines	39
15	Mantle cell lymphoma, low power showing neoplastic lymphoid cells surrounding small atrophic germinal center producing mantle zone pattern of growth	40
16	Mantle cell lymphoma, high power showing homogenous population of small lymphoid cells with somewhat irregular nuclear outlines resembling prolymphocytes ..	40
17	Diffuse large B-cell lymphoma; cells have large nuclei, open chromatin and large nucleoli	42
18	Burkitt's lymphoma; low power showing starry sky appearance	44
19	Burkitt's lymphoma; high power with cells having multiple small nucleoli and high mitotic index	45
20	Direct Immunoperoxidase Technique	53
21	Indirect Immunoperoxidase Technique	53
22	Placental Alkaline Phosphatase (PLAP): There is positive cytoplasmic staining for PLAP	56
23	S100 Protein: positive nuclear staining for S100	56

LIST OF FIGURES (CONT.)

Figure No.	Title	Page
24	Lymphoblastic lymphoma, TdT- positive Immunophenotyping protein	58
25	Small lymphocytic lymphoma, CD23- positive (IP)	59
26	Bcl-2 Expression in Reactive and Neoplastic Follicles, A; Bcl-2 is Present in Mantle Zone Cells but not Follicular Center B-cells, B; Follicular lymphoma show strong central bcl-2 Staining	60
27	Mantle cell lymphoma, Cyclin D1-positive (IP)	61
28	Diffuse large B-cell lymphoma, CD20-positive (IP)	62
29	Burkitt's lymphoma, EBV-positive (In situ hybridization)	63
30	Molecular configurations of human AFP (HAFP) (left), human albumin (ALB) (center), and human Gc vitamin-D binding protein	72
31	Diagrammatic representation of the proposed tri-domain structure of HAFP transitioning from the native to the Molten Globule (MG) state	72
32	Histo-RECAF on breast tumors. (A) Fibroadenoma (negative), 100X; (B) Ductal carcinoma, 200X; (C) Lobular carcinoma, 100X; (D) Axillary Lymph node metastasized by a breast carcinoma, 100X	79
33	Frozen sections of two different breast ductal carcinomas stained with RECAF	80

LIST OF FIGURES (CONT.)

Figure No.	Title	Page
34	Breast fine needle biopsies stained for RECAF: (A and B) Fibroadenomas	80
35	Different tissues stained with Histo-RECAF	81
36	Expression of AFP-R in gastric tissues.....	82
37	Positively Charged Slides.	91
38	Xylene Solution.	91
39	Primary Antibody (AFP Receptor Mouse Monoclonal Antibody).	92
40	Peroxidase Block	92
41	Secondary Antibody	93
42	Sterptavidin Peroxidase	94
43	DAB Plus Chromogen.	95
44	DAB Plus Substrate.	95
45	Placental tissue stained with RECAF (positive control)	97
46	Subgroups of B-NHL.....	122
47	LDH level in different B-NHL subgroups.....	122
48	Frequency of B-symptoms in different B-NHL subgroups .	123
49	Frequency of lymphadenopathy in different B-NHL subgroups	123
50	Comparison between the different stages in DLBCL.....	124

LIST OF FIGURES (CONT.)

Figure No.	Title	Page
51	Comparison between the different stages in FL	124
52	Frequency of HSM in different subgroups of B-NHL	125
53	Frequency of BM infiltration in different B-NHL subgroups	125
54	BM infiltration by RECAF in different B-NHL subgroups	126
55	Comparison between cases and PC groups as regards RECAF positive cases.	126
56	Comparison between non leukemic subgroups as regards RECA F positive cases.....	127
57	Comparison between histopathology and RECAF as regards BM infiltration in DLBCL	128
58	Comparison between histopathology and RECAF as regards BM infiltration in FL	128
59	Comparison between histopathology and RECAF as regards BM infiltration in MCL	128
60	ROC curve between patients and controls as regard RECAF.....	129
61	ROC curve between DLBCL and controls as regard RECAF	129

LIST OF FIGURES (CONT.)

Figure No.	Title	Page
62	ROC curve between FL and controls as regard RECAF.....	130
63	ROC curve between MCL and controls as regard RECAF.....	130
64	ROC curve between CLL and controls as regard RECAF.....	131
65	ROC curve between HCL and controls as regard RECAF.....	131

LIST OF ABBREVIATIONS

α	: Alpha.
Ab	: Antibody.
AEC	: Amino Ethyl Carbazole.
AFT	: Alpha Fetoprotein.
ALCL	: Anaplastic Large Cell Lymphoma.
ALK	: Anaplastic Lymphoma Kinase.
ALL	: Acute Lymphoblastic Lymphoma/Leukemia.
APC	: Antigen Presenting Cell.
β	: Beta.
Bcl-2	: Surface Antigen.
Bcl-6	: Surface Antigen.
BL	: Burkitt's lymphoma.
BM	: Bone Marrow.
CBC	: Complete Blood Count.
CD	: Cluster of Differentiation.
CD-40L	: CD-40 ligand.
CLL	: Chronic Lymphocytic Leukemia.
CML	: Chronic Myeloid Leukemia.
C-myc	: Oncogene.
CNS	: Central Nervous System.
CR	: Complete Response.
CRu	: Complete Response unconfirmed.
CSF	: Cerebro-Spinal Fluid.
CT	: Computed Tomography.
δ	: Delta.
DAB	: Diamino Benzedine tetrachloride.
DBP	: Vitamin-D Binding Protein.

LIST OF ABBREVIATIONS (Cont.)

DLBCL	: Diffuse Large B-Cell Lymphoma.
dl	: Deciliter.
DNA	: Deoxy Ribonucleic Acid.
DPX	: Mounting Solution.
EBV	: Epstein-Barr Virus.
EH	: Enzyme histochemistry.
EM	: Electron Microscopy.
ESR	: Erythrocyte Sedimentation Rate.
FCM	: Flow Cytometry.
FDC	: Follicular dendritic cells.
FG	: 18-Fluorodeoxy Glucose.
FISH	: Fluorescent in situ Hybridization.
FL	: Follicular Lymphoma.
FNA	: Fine Needle Aspirate.
g	: Gram.
γ	: Gamma.
GIP	: Growth Inhibitory Peptide.
GIT	: Gastro-Intestinal Tract.
Hb	: Hemoglobin.
HCC	: Hepato-Cellular Carcinoma.
HCL	: Hairy Cell Leukemia.
HD	: Hodgkin's Disease.
HIV	: Human Immunodeficiency Virus.
HHV-8	: Human Herpes Virus-8.
HL	: Hodgkin's Lymphoma.
HLA-DR	: Human Leukocyte Antigen Domain Receptor.
HSM	: Hepatosplenomegaly.